Published on: 5th February 2018
23 - 23 April 2018
British Medical Association
The Dementias Platform UK (DPUK) conference – a day-long event on 23 April this year in London – is focused on supporting use of the Data Portal, and demonstrating the wider work that will draw on its resource.
Researchers will be offered the chance to join practical workshops, learning alongside colleagues from a variety of sectors and contexts about what the Data Portal and other DPUK resources means for university researchers, and those working in industry in drug development. We are delighted to announce that the speakers at our annual conference 2018 are Professor Hugh Perry and Professor Miia Kivipelto.
By supporting as many researchers as possible to use the Data Portal, through both funding and ongoing training, DPUK hopes to increase the chances of generating new insights and accelerating our progress towards new treatments for dementia.
Sign up for your free place at the conference.
For more information please visit www.dementiasplatform.uk/forresearchers
Dementias Platform UK is a public-private partnership funded by the Medical Research Council. DPUK’s partners – ten universities and six pharmaceutical companies – have joined forces with the aim of accelerating research towards effective treatment for dementia by improving access to data.
By bringing together records from over 40 different cohort studies – including brain scans, genetics and clinical records – DPUK is creating the world’s richest source of people data for use in research and drug development for dementia. This free-to-access resource of cohort data is available for use by any bona fide researcher who is interested in investigating dementia, whether based within a university or industry context.
DPUK facilitates safe and secure access to this data through its Data Portal, enabling research and analyses at a scale that has not previously been possible for studies into dementia.
DPUK wishes to promote scientific research using cohort study data. It has an active programme of experimental medicine and funds research using cohort data.